HZNP logo

Horizon Therapeutics Public Limited (HZNP) EBITDA

Annual EBITDA

$1.00 B
+$103.39 M+11.52%

31 December 2022

3-Year Change

+35.15%
HZNP annual earnings before interest, taxes, depreciation & amortization is up +35.15% over the past 3 years

All-time High

$1.00 B
HZNP annual earnings before interest, taxes, depreciation & amortization is currently at an all-time high

Annual EBITDA Formula

Net Income + Interest + Taxes + Depreciation + Amortization
Annual Revenue$3.63 B
HZNP annual revenue is $3.63 billion
Annual Gross Profit$2.71 B
HZNP annual gross profit is $2.71 billion
Annual Net Income$521.48 M
HZNP annual net profit is $521.48 million

HZNP EBITDA Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly EBITDA

$243.63 M
+$114.03 M+87.99%

30 June 2023

3-Year Change

-42.63%
HZNP quarterly earnings before interest, taxes, depreciation & amortization is down -42.63% over the past 3 years

All-time High

$424.70 M
HZNP quarterly earnings before interest, taxes, depreciation & amortization is currently -42.63% below its historical high of $424.70 million
Quarterly Revenue$944.96 M
HZNP quarterly revenue is $944.96 million
Quarterly Gross Profit$725.00 M
HZNP quarterly gross profit is $725.00 million
Quarterly Operating Profit$140.84 M
HZNP quarterly operating income is $140.84 million
Quarterly Net Income$127.07 M
HZNP quarterly net profit is $127.07 million

HZNP Quarterly EBITDA Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM EBITDA

$901.54 M
+$60.01 M+7.13%

30 June 2023

3-Year Change

+2.61%
HZNP TTM earnings before interest, taxes, depreciation & amortization is up +2.61% over the past 3 years

All-time High

$1.27 B
HZNP TTM earnings before interest, taxes, depreciation & amortization is currently -29.21% below its historical high of $1.27 billion
TTM Revenue$3.64 B
HZNP TTM revenue is $3.64 billion
TTM Gross Profit$2.74 B
HZNP TTM gross profit is $2.74 billion
TTM Operating Profit$567.62 M
HZNP TTM operating income is $567.62 million
TTM Net Income$438.00 M
HZNP TTM net profit is $438.00 million

HZNP TTM EBITDA Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

HZNP EBITDA Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year---
3 y3 years+35.1%-42.6%+2.6%
5 y5 years+247.2%+261.4%+168.9%

HZNP EBITDA High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years
5 y5 years
alltimeall timeat high-42.6%-29.2%

Horizon Therapeutics Public Limited EBITDA History

DateAnnualQuarterlyTTM
June 2023
-
$243.63 M(+88.0%)
$901.54 M(+7.1%)
Mar 2023
-
$129.60 M(-52.3%)
$841.53 M(-15.9%)
Dec 2022
$1.00 B(+11.5%)
$271.67 M(+5.9%)
$1.00 B(-5.5%)
Sept 2022
-
$256.64 M(+39.8%)
$1.06 B(-13.7%)
June 2022
-
$183.62 M(-36.5%)
$1.23 B(-3.7%)
Mar 2022
-
$289.11 M(-12.3%)
$1.27 B(+41.9%)
Dec 2021
$897.64 M(+21.2%)
$329.63 M(-22.4%)
$897.64 M(+2.2%)
Sept 2021
-
$424.70 M(+84.5%)
$878.62 M(+19.0%)
June 2021
-
$230.13 M(-365.1%)
$738.37 M(+22.4%)
Mar 2021
-
-$86.82 M(-128.0%)
$603.42 M(-18.5%)
Dec 2020
$740.71 M(+143.6%)
$310.61 M(+9.2%)
$740.71 M(+36.2%)
Sept 2020
-
$284.45 M(+198.9%)
$543.90 M(+66.4%)
June 2020
-
$95.18 M(+88.6%)
$326.87 M(+7.9%)
Mar 2020
-
$50.47 M(-55.7%)
$302.85 M(-0.4%)
Dec 2019
$304.02 M(+5.4%)
$113.80 M(+68.8%)
$304.02 M(-9.3%)
Sept 2019
-
$67.42 M(-5.3%)
$335.21 M(-14.7%)
June 2019
-
$71.16 M(+37.8%)
$393.01 M(-0.4%)
Mar 2019
-
$51.64 M(-64.4%)
$394.78 M(+36.9%)
Dec 2018
$288.32 M(-478.4%)
$144.99 M(+15.8%)
$288.32 M(+74.9%)
Sept 2018
-
$125.22 M(+71.7%)
$164.89 M(+94.6%)
June 2018
-
$72.93 M(-233.0%)
$84.73 M(-187.9%)
Mar 2018
-
-$54.82 M(-354.2%)
-$96.37 M(+26.5%)
Dec 2017
-$76.20 M(-193.5%)
$21.56 M(-52.1%)
-$76.20 M(-52.5%)
Sept 2017
-
$45.06 M(-141.7%)
-$160.28 M(-4.6%)
June 2017
-
-$108.16 M(+212.1%)
-$167.95 M(-813.1%)
Mar 2017
-
-$34.66 M(-44.6%)
$23.55 M(-71.1%)
Dec 2016
$81.46 M
-$62.52 M(-267.2%)
$81.46 M(-58.6%)
Sept 2016
-
$37.39 M(-55.1%)
$196.96 M(-20.7%)
June 2016
-
$83.34 M(+258.4%)
$248.40 M(+182.1%)
DateAnnualQuarterlyTTM
Mar 2016
-
$23.25 M(-56.1%)
$88.06 M(+16.6%)
Dec 2015
$75.53 M(-135.7%)
$52.98 M(-40.4%)
$75.53 M(+415.4%)
Sept 2015
-
$88.84 M(-215.4%)
$14.66 M(-123.2%)
June 2015
-
-$77.01 M(-817.9%)
-$63.14 M(+1768.1%)
Mar 2015
-
$10.73 M(-235.8%)
-$3.38 M(-98.4%)
Dec 2014
-$211.85 M(+65.5%)
-$7.90 M(-171.5%)
-$211.85 M(-29.7%)
Sept 2014
-
$11.04 M(-164.0%)
-$301.41 M(-3.4%)
June 2014
-
-$17.25 M(-91.3%)
-$312.09 M(+1.2%)
Mar 2014
-
-$197.75 M(+102.9%)
-$308.26 M(+140.7%)
Dec 2013
-$128.04 M(+68.8%)
-$97.45 M(<-9900.0%)
-$128.04 M(+142.1%)
Sept 2013
-
$357.00 K(-102.7%)
-$52.90 M(-24.3%)
June 2013
-
-$13.42 M(-23.4%)
-$69.87 M(-7.0%)
Mar 2013
-
-$17.53 M(-21.4%)
-$75.14 M(-1.0%)
Dec 2012
-$75.88 M(-35.4%)
-$22.31 M(+34.2%)
-$75.88 M(-46.8%)
Sept 2012
-
-$16.62 M(-11.1%)
-$142.71 M(+1.4%)
June 2012
-
-$18.69 M(+2.3%)
-$140.72 M(+8.5%)
Mar 2012
-
-$18.26 M(-79.5%)
-$129.75 M(+10.9%)
Dec 2011
-$117.47 M(+440.6%)
-$89.14 M(+509.4%)
-$117.04 M(+475.3%)
Sept 2011
-
-$14.63 M(+89.4%)
-$20.34 M(+21.7%)
June 2011
-
-$7.72 M(+39.1%)
-$16.72 M(+4155.2%)
Mar 2011
-
-$5.55 M(-173.5%)
-$393.00 K(-83.3%)
Dec 2010
-$21.73 M(+16.1%)
$7.55 M(-168.7%)
-$2.35 M(-84.9%)
Sept 2010
-
-$11.01 M(-227.8%)
-$15.58 M(+78.3%)
June 2010
-
$8.61 M(-214.6%)
-$8.74 M(-59.8%)
Mar 2010
-
-$7.51 M(+32.3%)
-$21.74 M(+19.8%)
Dec 2009
-$18.71 M(-30.3%)
-$5.67 M(+36.4%)
-$18.16 M(+45.5%)
Sept 2009
-
-$4.16 M(-5.3%)
-$12.48 M(+50.0%)
June 2009
-
-$4.39 M(+12.0%)
-$8.32 M(+112.0%)
Mar 2009
-
-$3.92 M
-$3.92 M
Dec 2008
-$26.83 M
-
-

FAQ

  • What is Horizon Therapeutics Public Limited annual earnings before interest, taxes, depreciation & amortization?
  • What is the all time high annual EBITDA for Horizon Therapeutics Public Limited?
  • What is Horizon Therapeutics Public Limited quarterly earnings before interest, taxes, depreciation & amortization?
  • What is the all time high quarterly EBITDA for Horizon Therapeutics Public Limited?
  • What is Horizon Therapeutics Public Limited TTM earnings before interest, taxes, depreciation & amortization?
  • What is the all time high TTM EBITDA for Horizon Therapeutics Public Limited?

What is Horizon Therapeutics Public Limited annual earnings before interest, taxes, depreciation & amortization?

The current annual EBITDA of HZNP is $1.00 B

What is the all time high annual EBITDA for Horizon Therapeutics Public Limited?

Horizon Therapeutics Public Limited all-time high annual earnings before interest, taxes, depreciation & amortization is $1.00 B

What is Horizon Therapeutics Public Limited quarterly earnings before interest, taxes, depreciation & amortization?

The current quarterly EBITDA of HZNP is $243.63 M

What is the all time high quarterly EBITDA for Horizon Therapeutics Public Limited?

Horizon Therapeutics Public Limited all-time high quarterly earnings before interest, taxes, depreciation & amortization is $424.70 M

What is Horizon Therapeutics Public Limited TTM earnings before interest, taxes, depreciation & amortization?

The current TTM EBITDA of HZNP is $901.54 M

What is the all time high TTM EBITDA for Horizon Therapeutics Public Limited?

Horizon Therapeutics Public Limited all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.27 B